Amongst the highlights of triglyceride research presented at the American Heart Association Scientific Sessions 2026 (Chicago, USA, 6-9 November) were latest data from the TYDAL-TIMI 78 study of MAR001, the PALISADE and SHASTA-3/4 studies of plozasiran, together with early phase data with the dual action siRNA conjugate, ARO-DIMER-PA, the ANGPTL3 gene editing agent, CTX310, and the quaternary Gal-NAc siRNA, RN0361. There were also insightful real-world data from the USA about use of guideline recommended TG lowering agents in clinical practice.
Read the reports:
- TYDAL-TIMI 78 results support ANGPTL4 inhibition in HTG
- PALISADE and SHASTA-3/4 trials confirm sustained benefits of TG lowering with plozasiran
- TG-lowering therapy underused in patients at AP risk
- Novel dual action siRNA conjugate silences apoC3 and PCSK9
- ANGPTL3 gene editing therapy reduces TG in patients with sHTG
- Interim Phase 2a data with novel siRNA, RN0361
Reporting by Jenny Bryan
